Skip to main content

Advertisement

Table 3 Characteristics of patients

From: Recombinant human soluble thrombomodulin improves mortality in patients with sepsis especially for severe coagulopathy: a retrospective study

  Mild coagulopathy (n = 37) Severe coagulopathy (n = 32) P value
Male, n (%) 25 (67.6) 23 (71.9) 0.796
Age (years) 69 [38–94] 72.5 [33–91] 0.110
Shock, n (%) 14 (42.4) 13 (40.6) 1.000
AKI, n (%) 15 (42.9) 18 (56.3) 0.332
APACHE II score 26.6 ± 8.1 29.8 ± 10.8 0.229
SOFA score 6.2 ± 3.5 7.5 ± 2.5 0.114
ISTH overt DIC score 3.4 ± 0.7 5.3 ± 0.6 <  0.001
Mechanical ventilation, n (%) 31 (88.6) 30 (93.8) 0.675
Renal replacement therapy, n (%) 25 (71.4) 22 (68.8) 1.000
Vasopressor use, n (%) 24 (68.6) 24 (75.0) 0.598
Lactate (mmol/L) 32.0 ± 22.8 38.3 ± 21.5 0.289
Time for normalize lactate level (h) 94.8 ± 142.6 88.3 ± 87.0 0.854
Cancer, n (%) 6 (16.7) 5 (15.6) 1.000
rhTM dose (mg/kg) 0.041 ± 0.018 0.048 ± 0.023 0.218
Duration of rhTM administration (days) 5.4 ± 1.8 6.3 ± 3.5 0.181
Coagulation tests
 Prothrombin time ratio 1.34 ± 0.28 1.42 ± 0.26 0.212
 Antithrombin III activity (%) 57.7 ± 20.6 54.5 ± 21.8 0.581
 D-dimer (103 ng/ml) 14.0 ± 15.4 40.0 ± 65.0 <  0.001
 Platelet count (103/μl) 10.0 ± 10.1 5.3 ± 3.2 0.004
 Fibrinogen (mg/dl) 420.3 ± 216.7 410.0 ± 117.7 0.813
  1. Collected data are when rhTM administration start
  2. Data are presented as mean ± standard deviation unless otherwise stated. DIC: disseminated intravascular coagulation, AKI: acute kidney injury, APACHE II: acute physiologic and chronic health evaluation, SOFA: sequential organ failure assessment, ISTH: International Society on Thrombosis and Haemostasis, rhTM: recombinant human soluble thrombomodulin